PubMed: 33965067 Phase 2a: Weight Loss Efficacy Study (NCT03224429) Study Title: "Efficacy and Safety of Cagrilintide for Weight Management in Adults With Overweight or Obesity" Status: Completed Phase: Phase 2a Enrollment: 706 participants Study Period: 2018-2020 Location: Multi-country (US, Europe) Design: Randomized, double-blind, placebo-controlled Duration: 26 weeks Intervention: Cagrilintide 0.6/1.2/2.4/4.5 mg weekly Population: BMI 30 or 27 with comorbidity, no diabetes Key Results (26 Weeks): Mean Weight Loss: 10.8% at 4.5 mg (highest dose) 8.6% at 2.4 mg 6.0% at 1.2 mg 4.3% at 0.6 mg 3.0% with placebo 10% Weight Loss: 51% (4.5 mg) vs
Berberine has a long history in traditional Chinese medicine, where it has been used to treat various ailments ( Now, modern science suggests that it has impressive benefits for many health concerns ( Summary Berberine is a compound that can be extracted from several plants
It is very frequent to find that pupils have difficulty at first in spontaneously expressing their feelings about an audio- visual document
Cognitive behavioral therapy Drug therapy First-line antidepressants: selective serotonin reuptake inhibitors (SSRIs) eg, fluoxetine (Prozac) and citalopram (Celexa), serotonin-norepinephrine reuptake inhibitors (SNRIs) eg, duloxetine (Cymbalta) and venlafaxine (Effexor), and atypical antidepressants eg, bupropion (Wellbutrin) and mirtazapine (Remeron) Second-line antidepressants, including: tricyclic antidepressants eg, amitriptyline (Elavil) and clomipramine (Anafranil) monoamine oxidase inhibitors (MAOIs) eg, tranylcypromine (Parnate) and phenelzine (Nardil) Atypical antipsychotics: eg, aripiprazole (Abilify) and quetiapine (Seroquel) Neurostimulation techniques Electroconvulsive therapy Vagus nerve stimulation Repetitive transcranial magnetic stimulation Ablative neurosurgery What are Some Emerging Treatments for Depressive Disorders